Experimental Drug Shows Promise in Treating Alcohol Withdrawal Through Brain Inflammation Reduction

Research from the University of Kentucky suggests that an experimental dementia drug, MW150, may help alleviate alcohol withdrawal symptoms by reducing brain inflammation associated with addiction and relapse. This drug targets a specific brain inflammation pathway known as p38α MAPK and is being investigated as a treatment for mild to moderate Alzheimer’s disease.

Alcohol use disorder is notoriously challenging to treat, largely due to high relapse rates during withdrawal. Neuroinflammation is believed to contribute to the risk of relapse and long-term neurological damage. The study, published in the journal Alcohol, was conducted by the Sanders-Brown Center on Aging at the University of Kentucky and led by neuroinflammation researcher Linda Van Eldik.

In the research, MW150 was shown to reduce certain inflammatory markers in both laboratory and animal-model experiments during alcohol withdrawal. Caleb Bailey, Ph.D., co-author of the study, stated that these findings provide biological plausibility for MW150’s potential to mitigate neuroinflammation occurring due to alcohol withdrawal.

Bailey highlighted the importance of further experiments to confirm the anti-inflammatory effects of MW150 in animal models of alcohol use disorder. If successful, this could pave the way for the development of MW150 as a treatment for those with chronic alcohol relapse resulting from withdrawal.

Another drug, Neflamapimod, already in clinical trials for dementia and neurodegenerative conditions, shares similarities with MW150. This existing research gives added significance to the study, suggesting these compounds could potentially be repurposed for alcohol-related conditions if future studies show positive results.

However, Bailey noted the limitations of the current research, as it was primarily conducted in cell culture and animal models. This approach provides limited insights into the effects on a full organism or brain. A series of follow-up studies in living animals is necessary to fully understand the systemic health effects and impact on alcohol consumption of MW150 treatment in alcohol use and withdrawal.

Dr. Amy Swift, the deputy chief medical officer at Silver Hill Hospital, emphasized the need for supportive medications in treating alcohol use disorder. She noted that while detoxification helps prevent the potentially fatal complications of alcohol withdrawal, it doesn’t address the disorder itself. Reducing neuroinflammation might enhance a patient’s early engagement in treatment and positively affect their long-term relationship with alcohol.

Bailey concluded that minimizing alcohol consumption is crucial for maintaining physical health, as current pharmacological treatments do not effectively mitigate damage from chronic alcohol use. The interaction between MW150 and alcohol will be important for understanding patient outcomes as the drug continues to be studied for dementia treatment.